PROJECT ADDENDUM # TO AGREEMENT FOR THE DESIGN SERVICES FOR THE FOUR-YEARProject Addendum • January 20th, 2024
Whereas, the parties hereto have entered in the Agreement identified above (hereinafter referred to as the “Agreement”); and
Project:Project Addendum • April 27th, 2015
PROJECT ADDENDUM # TO AGREEMENT FOR THE DESIGN SERVICES FOR THE FOUR-YEAR ARCHITECT/ENGINEER SELECTION FROM MAY 1, 2015, THROUGH APRIL 30, 2019.
PROJECT ADDENDUM # TO AGREEMENT FOR THE DESIGN SERVICES FOR THE FOUR-YEARProject Addendum • January 20th, 2024
Whereas, the parties hereto have entered in the Agreement identified above (hereinafter referred to as the "Agreement"); and
PROJECT ADDENDUM # TO AGREEMENT FOR THE DESIGN SERVICES FOR THE FOUR-YEARProject Addendum • March 25th, 2010
Whereas, the parties hereto have entered in the Agreement identified above (hereinafter referred to as the "Agreement"); and
CONFIDENTIAL AND PROPRIETARY TO [ * * * ]Project Addendum • November 22nd, 2011 • Aastrom Biosciences Inc • Biological products, (no disgnostic substances)
THIS PROJECT ADDENDUM (the “Project Addendum”) is made and entered into as of November 16, 2011 (the “Effective Date”) by and between [ * * * ] and AASTROM BIOSCIENCES, INC., with its principal executive offices located at 24 Frank Lloyd Wright Drive, Lobby K, Ann Arbor Michigan 48105 (“Sponsor”).
Project AddendumProject Addendum • March 22nd, 2005 • Corautus Genetics Inc • Biological products, (no disgnostic substances)
THIS PROJECT ADDENDUM (the “Project Addendum”) is made and entered into as of March 7, 2005 (the “Effective Date”) by and between PPD DEVELOPMENT, LP, , a Texas limited partnership, with its principal executive offices located at 3151 South 17th Street, Wilmington, North Carolina 28412 (“PPD”) and CORAUTUS GENETICS, INC., a Delaware corporation, with its principal executive offices located at 75 Fifth Street, NW, Suite 313, Atlanta, GA 30308 (“Sponsor”).
PROJECT ADDENDUMProject Addendum • March 12th, 2015 • Galectin Therapeutics Inc • Pharmaceutical preparations • North Carolina
THIS PROJECT ADDENDUM (the “Project Addendum”) is made and entered into as of January 10, 2015 (the “Effective Date”) by and between PPD DEVELOPMENT, LP, a Delaware limited partnership, with its principal executive offices located at 929 North Front Street, Wilmington, North Carolina 28401 (“PPD”) and GALECTIN THERAPEUTICS, INC., a Nevada corporation with its principal executive offices located at 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, Georgia 30071 (“Sponsor”).
CONFIDENTIAL AND PROPRIETARY TO PPDProject Addendum • December 30th, 2016 • Vericel Corp • Biological products, (no disgnostic substances)
THIS PROJECT ADDENDUM (the “Project Addendum”) is made and entered into as of November 16, 2011 (the “Effective Date”) by and between PPD DEVELOPMENT, LP, a Texas limited partnership, with its principal executive offices located at 929 North Front Street, Wilmington, North Carolina 28401 (“PPD”) and AASTROM BIOSCIENCES, INC., with its principal executive offices located at 24 Frank Lloyd Wright Drive, Lobby K, Ann Arbor Michigan 48105 (“Sponsor”).
Project: <Project Name> Campus: <Campus and Address> Project No: <Project Number> Name of Architect or Engineering Firm: <Legal Name of Firm> Individual A/E Firm Contact:<Contact Name> Address: <Firm’s Address>Project Addendum • July 20th, 2022
PROJECT ADDENDUM <#>TO AGREEMENT FOR THE DESIGN SERVICES FOR THE FOUR-YEAR ARCHITECT/ENGINEER SELECTION FROM MAY 1, 2022, THROUGH APRIL 30, 2026.
to Agreement for On Demand Consulting Engineering Services for Systems Engineering ProjectsProject Addendum • August 8th, 2005
THIS PROJECT ADDENDUM is entered into on the day of , 2005 by and between the City of Overland Park, Kansas, (the “City”) and TransCore (the “Consulting Engineer”).
PROJECT ADDENDUMProject Addendum • October 4th, 2004 • Biovest International Inc • Pharmaceutical preparations
This Project Addendum (“Project Addendum”) made this 30th day of September 2004 (the “Effective Date”) is by and between BioVest International, Inc., with its principal executive offices located at 8500 Evergreen Boulevard, Minneapolis, Minnesota 55433 (“Sponsor”), and PPD Development, LP with its principal executive offices located at 3151 17th Street Extension, Wilmington, North Carolina 28412 (“PPD”).
to Agreement for On Demand Consulting Engineering Services for Systems Engineering ProjectsProject Addendum • August 8th, 2005
THIS PROJECT ADDENDUM is entered into on the day of , 2005 by and between the City of Overland Park, Kansas, (the “City”) and TransCore (the “Consulting Engineer”).
Project:Project Addendum • August 9th, 2011
PROJECT ADDENDUM # TO AGREEMENT FOR THE DESIGN SERVICES FOR THE FOUR-YEAR ARCHITECT/ENGINEER SELECTION FROM MAY 1, 2011, THROUGH APRIL 30, 2015.
PROJECT ADDENDUMProject Addendum • October 24th, 2007 • Reliant Pharmaceuticals, Inc. • Pharmaceutical preparations
This agreement (“Project Addendum”) made this 31 day of January, 2005 (the “Effective Date”) by and between Reliant Pharmaceuticals, Inc., with its principal executive offices located at 110 Allen Road, Liberty Corner, New Jersey (“Reliant” or “Client”), and PPD Development, LP, successor in interest to PPD Development, LLC, with its principal executive offices located at 3151 17th Street Extension, Wilmington, North Carolina 28412 (“PPD”).
